Evidence underlying the clinical management of diabetic macular oedema

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 13, Issue 4, 2013, Pages 353-357

  Williams, Michael Andrew ^a   Chakravarthy, Usha ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Diabetes; Macular; Retinopathy

Indexed keywords

AMINOGUANIDINE; BEVACIZUMAB; CANDESARTAN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; LISINOPRIL; RAMIPRIL; RANIBIZUMAB; RUBOXISTAURIN; SIMVASTATIN; TRIAMCINOLONE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD RETINA BARRIER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; LOW LEVEL LASER THERAPY; MACULAR THICKNESS; MASS SCREENING; PREGNANT WOMAN; PRIMARY PREVENTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NERVE CELL; RISK FACTOR; VISUAL ACUITY;

DIABETES; MACULAR; RETINOPATHY;

DIABETIC RETINOPATHY; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; MACULAR EDEMA;

EID: 84884528593     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.13-4-353     Document Type: Article

References (41)

1. Al-latayfeh MM, Sun JK, Aiello LP. Ocular coherence tomography and diabetic eye disease. Semin Opthalmol 2010;25:192-7.
2. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
3. Romero-Aroca P, Fernandez-Alart J, Baget-Bernaldiz M et al. Diabetic retinopathy epidemiology in type II diabetic patients. Effect of the changes in the diagnostic criteria and stricter control of the diabetes between 1993 and 2005 on the incidence of diabetic retinopathy. Arch Soc Esp Ofthalmol 2007;82:209-18.
4. Scholl S, Augustin A, Loewenstein A et al. General pathophysiology of macular edema. Eur J Opthalmol 2010;21:10-19.
5. Wu M, Chen Y, Wilson K et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:2679-85.
6. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:1156-63.
7. Rohan TE, Frost CD, Wald NJ. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ 1989;299:1198-201.
8. Chan WC, Lim LT, Quinn MJ et al. Management and outcome of sightthreatening diabetic retinopathy in pregnancy. Eye (Lond) 2004;18:826-32.
9. Lancet. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
10. BMJ. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
11. NEJM. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. NEJM. 1993;329:977-86.
12. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. NEJM 2008;358:2630-3.
13. Ranjit Unnikrishnan I, Anjana RM, Mohan V. Importance of controlling diabetes early-the concept of metabolic memory, legacy effect and the case for early insulinisation. The J Assoc Physicians India 2011;59 Suppl:8-12.
14. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
15. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. NEJM 2008;358:580-91.
16. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
17. Matthews DR. Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study. Evid Based Med 2011;16:45-6.
18. Wright AD, Dodson PM. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond). 2011;25:843-9.
19. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
20. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
21. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
22. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECTProtect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-93.
23. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye (Lond) 2010;24:1-6.
24. Ambrosius WT, Danis RP, Goff DC Jr, et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010;128:312-8.
25. Opthalmology. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766-85.
26. Beck RW, Edwards AR, Aiello LP et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51.
27. Jyothi S, Sivaprasad S. Five-year visual outcome following laser photocoagulation of diabetic macular oedema. Eye (Lond) 2011;25:851-8; quiz 59.
28. Elman MJ, Bressler NM, Qin H et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14.
29. Rajendram R, Fraser-Bell S, Kaines A et al. A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema: 24-Month Data: Report 3. Arch Ophthalmol 2012;130:972-9.
30. Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26.
31. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 2011;152:329-31.
32. Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 2010;21:377-9.
33. Sait-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLOS One 2008;3:e3554.
34. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 2009;23:1496-508.
35. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010;51:4867-74.
36. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Experimental diabetes research 2007;2007:61038.
37. Sheetz MJ, Aiello LP, Shahri N et al. Effect of ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina Philadelphia, Pa 2011;31:1053-9.
38. Stitt AW, O'Neill CL, O'Doherty MT et al. Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res 2011;30:149-66.
39. Rogers SL, Tikellis G, Cheung N et al. Retinal arteriolar caliber predicts incident retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes care 2008;31:761-3.
40. Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40.
41. A randomized trial of sorbinol, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinol Retinopathy Trial Research Group. Arch Ophthalmol 1990;108:1234-44.